Abstract: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is defined by compressible excipients. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

Abstract: Chewing gum are obtained by entrapping a liquid within a mass of gum, blast freezing the gum and entrapped liquid, and increasing the temperature to just below the melting point of the liquid, causing the liquid crystals to anneal. By manipulating the size and/or morphology of the frozen liquid crystals, one can thereby manipulate the internal structure of the gum. Optionally, the liquid can contain a drug in solution. If the solvent is then removed, the drug is left in the interstices of the gum. The rate of release of the drug from the gum is thus determined by the distribution of the drug within the gum arising from the annealing step. This method of manufacturing a chewing gum avoids the use of elevated temperatures, and is particularly suitable for entrapping thermolabile substances.

Abstract: A tooth whitening chewing gum composition effective to remove stains from teeth is prepared from a mixture of a chewing gum base, plasticizing, sweetening, flavoring agents, and about 0.5 to about 5.0% by weight of a silica particles, the particles containing about 5 to about 35% by weight water and having a mean particle size from 5 to 12 microns; an Einlehner hardness of from 1 to 20; an oil absorption value of from 40 to less than 100 cc/i 00g; and, a BET surface area from 100 to 700 m2/g of silica.

Abstract: The present invention is directed to ACE inhibitor-containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.

Abstract: A dietary supplement for mammalian consumption, and particularly human consumption, for the purpose of stimulating the immune system, inhibiting infection and increasing tissue repair and healing. Comprising colostrum, lactoferrin, and with modified citrus pectin as an optional component, the dietary supplement is administered in ‘mucosal delivery format’: a dosage form that promotes effective absorption through the lining of the oral cavity.

Abstract: A kit and associated method in which symptoms of nicotine withdrawal syndrome are relieved as well as addressing the associated weight gain issues and craving for sweets by combining nicotine replacement therapy with complementary dosages of xylitol.

Abstract: A comestible product which includes inulin, a second component and a divalent zinc or copper. When the comestible product is a tablet, a pressed tablet, a lozenge, a hard candy or a chewy candy, the second component is a formentable carbohydrate which may, optionally, include a polyol. When the comestible product is a chewing gum the second component is a polyol, a formentable carbohydrate or mixtures thereof. The comestible product is useful in controlling breath malodor.

Abstract: The present invention pertains to a method for providing dental hygiene which method employs a low moisture chewing gum or confectionery product containing as active ingredients, a combination of sodium bicarbonate and casein phosphopeptide-amorphous calcium phosphate. The invention also concerns the chewing gums and confectionery products that can provide dental health benefits and methods for their preparation.

Abstract: Candy food, a piece of confectionery, which is a small, hard, chewy, or soft piece of food made from sugar and other ingredients or flavorings, such as chocolate, nuts, fruit, or peppermint is provided with enhanced refreshing properties of deacidifying the mouth and a stomach from the food or drink just consumed as well as reducing mouth, throat, esophageal, or other gastrointestinal irritation, together with reducing the incidence of dental caries and delivering absorbable calcium and phosphorus, wherein said candy food comprises combining a candy component with an effective amount of calcium glycerophosphate.

Abstract: Chewing gums are obtained by entrapping a liquid within a mass of gum, blast freezing the gum and the entrapped liquid, and increasing the temperature of the gum to just below the melting point of the liquid, causing the liquid crystals to anneal. By manipulating the size and/or morphology of the frozen liquid crystals, one can thereby manipulate the internal structure of the gum. Optionally, the liquid can contain a drug in solution. If the solvent is then removed, the drug is left in the interstices of the gum. The rate of release of the drug from the gum is thus determined by the distribution of the drug within the gum arising from the annealing step. This method of manufacturing a chewing gum avoids the use of elevated temperatures, and is thus particularly suitable for entrapping thermolabile substances.

Abstract: Controlled release powder insufflation formulations are disclosed. The powder formulation includes cohesive composites of particles containing a medicament and a controlled release carrier which preferably includes one or more polysaccharide gums of natural origin.

Abstract: The subject invention is a carrier or product formed of a matrix having starch, sugar, fat, polyhydric alcohol and water in suitable ratios such that there exists a water activity of 0.6-0.75. The water activity of the product matrix may be adjusted up or down so that the availability of water in the finished product is not detrimental to the included active ingredient, be it pharmaceutical, nutraceutical, or a vitamin mineral complex.

Abstract: The invention relates to concomitant treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the ulcer cure rate and prevent ulcer relapse. The invention also provides oral topical dosage forms with pharmaceutically usable bismuth compounds, other antibacterial compounds, and/or antibiotics that eradicate or reduce H. pylori in dental plaque. The invention further provides for treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compounds which have applications in wound healing, particularly in ocular and dermal wound healing.

Abstract: The inventions relates to a dragee chewing sweet with a soft caramel core and a dragee coating, whereby the chewing sweet contains a sweetener mixture that is sugar-free.

Abstract: The present invention relates generally to a complete nutritional product that provides soy protein and enhanced levels of isoflavones. Preferably, the soy protein comprises at least 0.7 mg isoflavones/gm soy protein and at least 0.5 mg genistein/gm soy protein. The product is fortified at 35% of the RDI for calcium and contains an antioxidant package. The invention also describes the method to produce a heat stable isoflavone-enriched soy protein complete nutritional.

Abstract: A novel encapsulated product is provided and includes: at least one active ingredient; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. The encapsulated product may be incorporated into a food item, a soft confectionery product, a hard confectionery product, a jelly gum confectionery product, and a dry beverage or chewing gum product.

Abstract: The invention relates to a pulverulent sorbitol, characterized in that it exhibits a hygroscopicity value, determined according to a test A, of less than 2%, preferably of less than 1.7%, and a specific surface, determined according to the BET method, at least equal to 2 m2/g, preferably at least equal to 2.2 m2/g, and also relates to its process of preparation. The invention also relates to compositions intended in particular for the food and pharmaceutical fields and to the use of the said pulverulent sorbitol in the preparation of tablets exhibiting a <<smooth in the mouth>> texture.

Abstract: A method of blocking free radical processes in an animal which result in mediated pathology without deleterious pro-oxidant side reactions which comprises administering an extract of the fruit of the Emblica officinalis plant to effect such advantageous result, preferably in a use formulation at an active use level of 0.005 to 5% by weight of the formulation.

Abstract: An oral composition comprises an antibacterial effective amount of cetylpyridinium chloride, an effective amount of guar hydroxypropyltrimonium chloride, sufficient to bind to compounds which undesirably bind to cetylpyridinium chloride thereby enabling the cetylpyridinium chloride to effectively bind to tooth surfaces and perform an antibacterial function, and an orally acceptable carrier.

Abstract: Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Abstract: The present inventive subject matter is directed to novel chewable prenatal nutritional supplements which contain vitamin C, as well as novel methods for providing optimal vitamin C supplementation to pregnant women. The present invention is also directed to novel compositions and methods for providing nutritional supplementation to individuals planning to conceive a child.

Abstract: A method for producing a chewing gum with an improved release of a lipophilic active agent, as well as the chewing gum so produced, is obtained by using a hydrophilic gum base. The preferred and novel gum base includes hydrophilic polymers, hydrophilic softeners/emulsifiers and fillers, but is essentially free of hydrophobic elastomers and hydrophobic softeners, as well as waxes and elastomer solvents. The lipophilic active agent is preferably added to a coating on a chewing gum pellet made using a hydrophilic gum base, such as by being mixed into a coating solution. The coating solution may contain a high-intensity sweetener. An active agent may also be used in the gum core.

Abstract: The composition comprises a mixture of olive oil (Olea europea L.) and parsley oil (Petroselinum sativum Hoffm., Petroselinum crispum Mill., Carum petroselinum Benth & Hooker), in a ratio of olive oil:parsley oil, by weight, comprised between 1 and 7. Additionally the composition may contain other vegetable oils, mint oil, menthol and chlorophyll. These compositions may be presented in several forms including sweets, chewing-gum, dentifrice paste, mouthwashes and pharmaceutical compositions, especially as soft gelatine capsules, for which purpose they incorporate the suitable additives, vehicles and excipients for its processing in the desired form of presentation. The composition is suitable for the treatment of is halitosis.

Abstract: A chewing gum delivery system has nicotine, gum base and a buffer system with an improved release rate for the nicotine. The resulting delivery system advantageously provides a convenient, reliable, practical, and relatively painless system for delivering an active. The delivery system is capable of delivering initial and second doses of a craving reduction active or other actives (e.g., nicotine), the combination of which rapidly reduces cravings, or provides some other pharmacological effect, and provides the pharmacological effect or protection from such cravings over a prolonged period of time beyond the initial dose. Notably, the delivery system is capable of rapidly achieving a pharmacologically effective concentration of the active (e.g., nicotine) in the bloodstream (e.g.

Abstract: The present invention discloses a method for treating dental caries, comprising administering a composition comprising an effective amount of at least one lytic enzyme produced by a bacteriophage specific for said bacteria, the lytic enzyme having the ability to digest a cell wall of the bacteria infecting all or part of a mouth or teeth, and a carrier for delivering the enzyme to the mouth and teeth.

Abstract: A method for reducing postprandial oxidative stress and associated pathologies by the dietary intake of cocoa procyanidins, such as epicatechin is disclosed.

Abstract: The present invention relates to methods of treating periodontal disease in a mammal. The methods include administering to an animal an s effective amount of an inhibitor of sPLA2. The inhibitors may be advantageously delivered as a composition that includes various carriers. In certain aspects of the invention, inhibitors used in the method include substituted indole or substituted pyrrole sPLA2 inhibitors. Also provided are compositions that include the sPLA2 carriers for oral delivery of the inhibitors.

Abstract: The present invention discloses a method for treating Streptococcal infections of the upper respiratory tract, comprising administering an effective amount of a lysin enzyme produced by group C Streptococcal bacteria infected with a C1 bacteriophage specific for the bacteria to a mouth, throat, or nasal passage of a mammal, the method providing a concentration of from about 100 to 500,000 active enzyme units per milliliter of fluid in the environment of said nasal or oral passages.

Abstract: The present invention provides a process for preparing a chewing gum tablet, in which a chewing gum composition is cooled to a temperature at which the composition is brittle, and the composition is ground while brittle to form a fine powder. In a preferred process, the composition is cooled by mixing with a coolant, such as solid carbon dioxide, and the mixture is ground to a powder. The powder can be mixed with a pharmaceutical active ingredient capable of topical absorption in the buccal cavity or in the mucous layer of the upper or lower intestinal tract, and formed into a tablet. Preferably, the mixture of the powder, pharmaceutical active ingredient, and other additives such as coating agents, binders, additional active ingredients, and sweeteners, are granulated in a fluidized bed granulator prior to forming the mixture into a tablet. The resulting tablet provides a dosage form of the pharmaceutical active ingredient having a more accurate and uniform dose of the active ingredient.

Abstract: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Abstract: The present invention describes methods for preventing and treating sexual dysfunctions in patients by orally administering at least one &agr;-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo. The present invention also describes orally administrable compositions comprising at least one &agr;-adrenergic receptor antagonist and at least one compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo. In the present invention, the &agr;-adrenergic receptor antagonist is preferably yohimbine or phentolamine, and the compound that elevates endogenous nitric oxide or endothelium-derived relaxing factor in vivo is preferably L-arginine.

Abstract: A composition in the form of a chewing gum composition or a confectionery composition containing stain removing agent selected from anionic and non-ionic surfactants and methods of preparing and using the same to remove stains from dental material including teeth.

Abstract: The invention relates to cocoa sphingolipids, cocoa extracts containing cocoa sphingolipids, and compositions containing cocoa sphingolipids and/or metabolic derivatives thereof. The invention also relates to methods of isolating and purifying sphingolipids and methods of using the cocoa sphingolipids and/or metabolic derivatives thereof.

Abstract: A dietary supplement for enhancing physical performance of human subjects is disclosed. The supplement in dry, finely-divided form includes as a major ingredient a soy protein isolate containing at least 80% protein on a moisture-free basis with lesser amounts of carbohydrate, free form amino acids, medium chain triglycerides, creatine monohydrate, l-carnitine, grape seed extract, coenzyme Q10, piper nigrum extract, and alpha lipoic acid. In a preferred embodiment, the supplement also includes minor amounts of conjugated linoleic acid and phosphatidylserine/phosphatidylcholine complex.

Abstract: Compositions for oral use containing at least one zinc compound, at least one amino acid, a source of ascorbic acid which does not appreciably associate with zinc ions, and a base material. The compositions provide for slow release of zinc upon dissolution in the mouth. The amino acid provides the zinc compound(s) with a palatable taste and no aftertaste. The source of ascorbic acid provides Vitamin C without interacting with zinc and forming unpalatable by-products. A method for making such compositions is also described.

Abstract: A polymer useful in oral care compositions which has a reactive group covalently bonded to a bactericide, flavorant and/or essential oil compound, said bond being hydrolyzable in aqueous solution to slowly release said compound into said composition.

Abstract: Throat drops suitable for relief of cough and cold symptoms comprise a cooling composition and a warming composition in distinct and discrete regions thereof, the cooling and warming compositions being adapted to provide sequential relief profiles. The cooling composition includes from about 0.001% to about 10%, by weight, cooling agent, and the warming composition comprises from about 0.001% to about 1.0%, by weight, warming agent.

Abstract: A non-food anti-microbial-adhesion and aggregation composition comprising a suitable carrier and an effective amount of an adhesion inhibitory fraction isolated from juice from berries of the Vaccinium plant genus. In an embodiment the anti-aggregation and adhesion fraction is isolated from cranberry juice. It is characterized as being polymeric and having a molecular weight ≧14,000; an elemental analysis of carbon 43-51%, hydrogen 4-5%, no nitrogen, no sulfur and no chlorine; a nuclear magnetic resonance (NMR) line spectrum as set forth in FIGS. 2A and 2B; and an ultraviolet spectrum with an absorption peak at 280 nm in neutral or acidic pH solution which is absent in alkali solutions. This fraction exhibits adhesion inhibitory activity against P fimbriated bacteria, oral bacteria and Helicobacter pylori.

Abstract: A method for manufacturing an antidotal food product containing activated charcoal is provided to combine a binder, a filler composition, water, flavoring and sweetener compositions with an activated charcoal to form wafers having a consistency emulating that of a baked cookie. The activated charcoal (110), binder (112), filler (114), water (116), and flavoring and sweetener compositions (118) are combined in a mixer (210) to form a slurry. The slurry is then processed in a spray dryer (220) to form granules. The granules are combined with a lubricant (122) in a blender (230). The dry mixture from blender (230) is then formed into wafers by a tableting type machine in a compression molding step (240). The wafers formed in the compression molding step (240) are then coated in an anti-dusting coating step (250). A sweet creme filling is applied between pairs of the wafers in a cookie sandwich assembly step (270).

Abstract: An oral composition in the form of a toothpaste, powder, liquid dentifrice, mouthwash, denture cleanser, chewing gum or candy comprising a lipophilic compound selected from flavorants, physiological cooling agents and antimicrobial compounds and a dimethicone copolyol selected from alkyl- and alkoxy-dimethicone copolyols having the formula (I): wherein X is selected from hydrogen, alkyl, alkoxy and acyl groups having from about 1 to about 16 carbon atoms, Y is selected from alkyl and alkoxy groups having from about 8 to about 22 carbon atoms, n is from about 0 to about 200, m is from about 1 to about 40, q is from about 1 to about 100, the molecular weight of the residue (C2H4O—)x(C3H6O—)yX is from about 50 to about 2000, and x and y are such that the weight ratio of oxyethylene:oxypropylene is from about 100:0 to about 0:100.

Abstract: A non-toxic, edible, enteric film coating, dry powder composition for use in making an aqueous enteric suspension which may be used in coating pharmaceutical tablets comprises a) an acrylic resin, said resin comprising i) from 20 to 85 percent by weight of at least one alkyl acrylate or alkyl methacrylate moiety, ii) from 80 to 15 percent by weight of at least one vinyl or vinylidene moiety having a carboxylic acid group capable of salt formation, and iii) from 0 to 30 percent by weight of at least one other vinyl or vinylidene moiety copolymerizable with i) and ii), b) an alkalizing agent capable of reacting with the acrylic resin such that, after reaction, 0.1 to 10 mole percent of the acidic groups in 1a-ii) are present in the salt form, and c) a detacktifier.

Abstract: A method of inhibiting blood platelet aggregation in humans which comprises administering an extract blend of the fruit of the Emblica officinalis plant to control said aggregation, suitably in a dose amount of about 50-500 mg/day.

Abstract: The present invention provides compositions comprising complexes of &bgr;-lactoglobulin with particular lipophilic nutrients, in particular vitamin E and vitamin K1. Preferably, bioselective absorption is employed to isolate &bgr;-Lg for use as a carrier protein. Also provided are food compositions and topical compositions comprising complexes of &bgr;-lactoglobulin and a lipophilic nutrient.

Abstract: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Abstract: A composition for the control of smoking which comprises: (a) a flavonoid in the form of an extract from Eupatorium purpurem preferably euparani; (b) a cytochrome P45C inhibitor (c) a sugar; (d) a source of phosphate; and, optionally, (e) one or more pharmaceutically acceptable carriers.

Abstract: A method for smoking cessation therapy is described that utilizing an improved nicotine lozenge to satisfy transient craving. The lozenge contains nicotine, a nonnutritive sweetener and an absorbent excipient.

Abstract: A throat drop comprises from 60 to 95% of a candy shell and from 5 to 40% of an aqueous filling, by weight of the drop. The filling comprises, by weight, by 8 to 20% water, from 50 to 85% bulk sweetener, and sufficient emulsifier to provide a contact angle of from 90° to 120°, the filling having a contact angle of greater than 120° in the absence of the emulsifier. The reduction in contact angle relative to a composition without the emulsifier provides an improved perception of liquidity of the filling.

Abstract: An pharmacological element, generally configured in the shape of a tablet, for the transmucosal administration of nicotine is made to effect the equivalent physiological and psychological responses of smoking a cigarette. The element is made by placing between 0.5 mg and 5 mg of nicotine in a layer upon a non-nicotine containing matrix. The nicotine containing layer rapidly dissolves by the warmth and saliva in the mouth. The nicotine is then rapidly absorbed by the intra-oral mucosal surfaces of the mouth, and then felt as a sharp pulse in the brain in a period of less than two minutes, but usually in less than 30 seconds. A multi-layered element is also provided where the nicotine is placed in a plurality of layers separated by one or more layers that are essentially free of nicotine to support the nicotine containing layers, and, to provide a time delay between the sharp pulses produced by the nicotine containing layers.

Abstract: The invention relates to a pulverulent sorbitol, characterized in that it exhibits a hygroscopicity value, determined according to a test A, of less than 2%, preferably of less than 1.7%, and a specific surface, determined according to the BET method, at least equal to 2 m2/g, preferably at least equal to 2.2 m2/g, and also relates to its process of preparation. The invention also relates to compositions intended in particular for the food and pharmaceutical fields and to the use of the said pulverulent sorbitol in the preparation of tablets exhibiting a <<smooth in the mouth>> texture.

Abstract: The present invention relates to an oral care composition comprising a Cellulose Binding Domain and further ingredient conventionally used in oral care compositions, oral care products, and the use of CBDs for oral care purposes.